Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
Perrone G, Hideshima T, Ikeda H, Okawa Y, Calabrese E, Gorgun G, Santo L, Cirstea D, Raje N, Chauhan D, Baccarani M, Cavo M, Anderson KC. Perrone G, et al. Among authors: cirstea d. Leukemia. 2009 Sep;23(9):1679-86. doi: 10.1038/leu.2009.83. Epub 2009 Apr 16. Leukemia. 2009. PMID: 19369963
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
Eda H, Santo L, Cirstea DD, Yee AJ, Scullen TA, Nemani N, Mishima Y, Waterman PR, Arastu-Kapur S, Evans E, Singh J, Kirk CJ, Westlin WF, Raje NS. Eda H, et al. Among authors: cirstea dd. Leukemia. 2014 Sep;28(9):1892-901. doi: 10.1038/leu.2014.69. Epub 2014 Feb 12. Leukemia. 2014. PMID: 24518207
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, Cirstea D, Pozzi S, Mitsiades C, Rooney M, Kiziltepe T, Podar K, Okawa Y, Ikeda H, Carrasco R, Richardson PG, Chauhan D, Munshi NC, Sharma S, Parikh H, Chabner B, Scadden D, Anderson KC. Raje N, et al. Among authors: cirstea d. Leukemia. 2009 May;23(5):961-70. doi: 10.1038/leu.2008.378. Epub 2009 Jan 8. Leukemia. 2009. PMID: 19151776
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.
Cirstea D, Hideshima T, Santo L, Eda H, Mishima Y, Nemani N, Hu Y, Mimura N, Cottini F, Gorgun G, Ohguchi H, Suzuki R, Loferer H, Munshi NC, Anderson KC, Raje N. Cirstea D, et al. Leukemia. 2013 Dec;27(12):2366-75. doi: 10.1038/leu.2013.194. Epub 2013 Jun 28. Leukemia. 2013. PMID: 23807770 Free PMC article.
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC. Minami J, et al. Among authors: cirstea d. Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub 2013 Aug 5. Leukemia. 2014. PMID: 23913134 Free PMC article.
CSNK1α1 mediates malignant plasma cell survival.
Hu Y, Song W, Cirstea D, Lu D, Munshi NC, Anderson KC. Hu Y, et al. Among authors: cirstea d. Leukemia. 2015 Feb;29(2):474-82. doi: 10.1038/leu.2014.202. Epub 2014 Jun 25. Leukemia. 2015. PMID: 24962017 Free PMC article.
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC. Suzuki R, et al. Among authors: cirstea d. Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300. Epub 2014 Oct 13. Leukemia. 2015. PMID: 25306900 Free PMC article. No abstract available.
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N. Cirstea D, et al. Mol Cancer Ther. 2010 Apr;9(4):963-75. doi: 10.1158/1535-7163.MCT-09-0763. Epub 2010 Apr 6. Mol Cancer Ther. 2010. PMID: 20371718 Free PMC article.
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S, Patel K, Okawa Y, Gorgun G, Perrone G, Calabrese E, Yule M, Squires M, Ladetto M, Boccadoro M, Richardson PG, Munshi NC, Anderson KC, Raje N. Santo L, et al. Among authors: cirstea d. Oncogene. 2010 Apr 22;29(16):2325-36. doi: 10.1038/onc.2009.510. Epub 2010 Jan 25. Oncogene. 2010. PMID: 20101221 Free PMC article.
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC. Vallet S, et al. Among authors: cirstea d. Blood. 2007 Nov 15;110(10):3744-52. doi: 10.1182/blood-2007-05-093294. Epub 2007 Aug 22. Blood. 2007. PMID: 17715391 Free PMC article.
Fatty acid synthase is a novel therapeutic target in multiple myeloma.
Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC. Okawa Y, et al. Among authors: cirstea d. Br J Haematol. 2008 May;141(5):659-71. doi: 10.1111/j.1365-2141.2008.07114.x. Epub 2008 Apr 10. Br J Haematol. 2008. PMID: 18410446 Free PMC article. Retracted.
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC. Ikeda H, et al. Among authors: cirstea d. Clin Cancer Res. 2009 Jun 15;15(12):4028-37. doi: 10.1158/1078-0432.CCR-08-2867. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509164
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.
Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N. Vallet S, et al. Among authors: cirstea d. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5124-9. doi: 10.1073/pnas.0911929107. Epub 2010 Mar 1. Proc Natl Acad Sci U S A. 2010. PMID: 20194748 Free PMC article.
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC. Görgün G, et al. Among authors: cirstea d. Blood. 2010 Jun 24;115(25):5202-13. doi: 10.1182/blood-2009-12-259523. Epub 2010 Apr 9. Blood. 2010. PMID: 20382844 Free PMC article.
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC. Görgün G, et al. Among authors: cirstea d. Blood. 2010 Oct 28;116(17):3227-37. doi: 10.1182/blood-2010-04-279893. Epub 2010 Jul 22. Blood. 2010. PMID: 20651070 Free PMC article.
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N. Santo L, et al. Among authors: cirstea d. Clin Cancer Res. 2011 May 15;17(10):3259-71. doi: 10.1158/1078-0432.CCR-10-3012. Epub 2011 Mar 23. Clin Cancer Res. 2011. PMID: 21430070 Free PMC article.
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N. Santo L, et al. Among authors: cirstea d. Blood. 2012 Mar 15;119(11):2579-89. doi: 10.1182/blood-2011-10-387365. Epub 2012 Jan 19. Blood. 2012. PMID: 22262760 Free PMC article.
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC. Mimura N, et al. Among authors: cirstea d. Blood. 2012 Jun 14;119(24):5772-81. doi: 10.1182/blood-2011-07-366633. Epub 2012 Apr 26. Blood. 2012. PMID: 22538852 Free PMC article.
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC. Fabre C, et al. Among authors: cirstea d. Clin Cancer Res. 2012 Sep 1;18(17):4669-81. doi: 10.1158/1078-0432.CCR-12-0779. Epub 2012 Jul 17. Clin Cancer Res. 2012. PMID: 22806876 Free PMC article.
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L, Kuhstoss S, Anderson KC, Munshi N, Scadden D, Kronenberg HM, Raje N. Pozzi S, et al. Among authors: cirstea d. Bone. 2013 Apr;53(2):487-96. doi: 10.1016/j.bone.2013.01.012. Epub 2013 Jan 17. Bone. 2013. PMID: 23333523 Free PMC article.
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC. Mimura N, et al. Among authors: cirstea d. Cancer Res. 2014 Aug 15;74(16):4458-69. doi: 10.1158/0008-5472.CAN-13-3652. Epub 2014 Jun 16. Cancer Res. 2014. PMID: 24934808 Free PMC article.
Role of decorin in multiple myeloma (MM) bone marrow microenvironment.
Nemani N, Santo L, Eda H, Cirstea D, Mishima Y, Patel C, O'Donnell E, Yee A, Raje N. Nemani N, et al. Among authors: cirstea d. J Bone Miner Res. 2015 Mar;30(3):465-70. doi: 10.1002/jbmr.2371. J Bone Miner Res. 2015. PMID: 25407518 Free article.
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H, Yoshida Y, Sagawa M, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi N, Ando K, Utsugi T, Hideshima T, Anderson KC. Suzuki R, et al. Among authors: cirstea d. PLoS One. 2015 Dec 2;10(12):e0143847. doi: 10.1371/journal.pone.0143847. eCollection 2015. PLoS One. 2015. PMID: 26630652 Free PMC article.
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, Rosen E, Ikeda H, Okawa Y, Kiziltepe T, Schoonmaker J, Xie W, Hideshima T, Weller E, Bouxsein ML, Munshi NC, Anderson KC, Raje N. Pozzi S, et al. Among authors: cirstea d. Clin Cancer Res. 2009 Sep 15;15(18):5829-39. doi: 10.1158/1078-0432.CCR-09-0426. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737962
Novel therapeutic targets for multiple myeloma.
Mahindra A, Cirstea D, Raje N. Mahindra A, et al. Among authors: cirstea d. Future Oncol. 2010 Mar;6(3):407-18. doi: 10.2217/fon.10.2. Future Oncol. 2010. PMID: 20222797 Review.
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS. Yee AJ, et al. Among authors: cirstea dd. Br J Haematol. 2014 Aug;166(3):401-9. doi: 10.1111/bjh.12909. Epub 2014 Apr 25. Br J Haematol. 2014. PMID: 24761838 Free article. Clinical Trial.
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.
Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC. Hideshima T, et al. Among authors: cirstea d. Blood. 2017 Mar 9;129(10):1308-1319. doi: 10.1182/blood-2016-09-738500. Epub 2017 Jan 12. Blood. 2017. PMID: 28082445 Free PMC article.
Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors.
Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Subramanian R, Carmody LC, Yusuf RZ, Sykes DB, Paulk J, Vetere A, Vallet S, Santo L, Cirstea DD, Hideshima T, Dančík V, Majireck MM, Hussain MM, Singh S, Quiroz R, Iaconelli J, Karmacharya R, Tolliday NJ, Clemons PA, Moore MAS, Stern AM, Shamji AF, Ebert BL, Golub TR, Raje NS, Scadden DT, Schreiber SL. Chattopadhyay S, et al. Among authors: cirstea dd. Cell Rep. 2015 Feb 10;10(5):755-770. doi: 10.1016/j.celrep.2015.01.017. Epub 2015 Feb 5. Cell Rep. 2015. PMID: 25660025 Free PMC article.
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.
Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC. Fabre C, et al. Among authors: cirstea d. Clin Cancer Res. 2019 May 1;25(9):2938. doi: 10.1158/1078-0432.CCR-19-0959. Clin Cancer Res. 2019. PMID: 31043386 No abstract available.
Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System.
DuMontier C, Fillmore NR, Yildirim C, Cheng D, La J, Orkaby AR, Charest B, Cirstea D, Yellapragada S, Gaziano JM, Do N, Brophy MT, Kim DH, Munshi NC, Driver JA. DuMontier C, et al. Among authors: cirstea d. Cancers (Basel). 2021 Jun 18;13(12):3053. doi: 10.3390/cancers13123053. Cancers (Basel). 2021. PMID: 34207459 Free PMC article.
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.
Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, Rivero G, Zimolzak A, Pyarajan S, Do N, Brophy M, Munshi NC. Fillmore NR, et al. Among authors: cirstea d. Blood. 2019 Jun 13;133(24):2615-2618. doi: 10.1182/blood.2019000406. Epub 2019 Apr 19. Blood. 2019. PMID: 31003998 Free PMC article. No abstract available.
[Relevance of fluoroquinolone use in Lorraine: results of the first survey].
Doco-Lecompte T, Demoré B, Burty C, Rondelot G, Scheid P, Zuck P, Simon L, Letranchant L, Robert C, Frentiu E, Petitfrère M, Simplot B, Bevilacqua S, Voltz C, Rabaud C, May T; le réseau Antibiolor. Doco-Lecompte T, et al. Med Mal Infect. 2010 Feb;40(2):106-11. doi: 10.1016/j.medmal.2009.08.022. Epub 2009 Oct 8. Med Mal Infect. 2010. PMID: 19818570 French.
Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie).
Tiev KP, Diot E, Clerson P, Dupuis-Siméon F, Hachulla E, Hatron PY, Constans J, Cirstéa D, Farge-Bancel D, Carpentier PH. Tiev KP, et al. Among authors: cirstea d. J Rheumatol. 2009 Jul;36(7):1470-6. doi: 10.3899/jrheum.081044. Epub 2009 Jun 1. J Rheumatol. 2009. PMID: 19487271
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France.
Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, Mouthon L, Hatron PY, Jego P, Allanore Y, Tiev KP, Agard C, Cosnes A, Cirstea D, Constans J, Farge D, Viallard JF, Harle JR, Patat F, Imbert B, Kahan A, Cabane J, Clerson P, Guillevin L, Humbert M; Itinér AIR-Sclérodermie Study Group. Hachulla E, et al. Among authors: cirstea d. Arthritis Rheum. 2009 Jun;60(6):1831-9. doi: 10.1002/art.24525. Arthritis Rheum. 2009. PMID: 19479881 Free article.
Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study.
Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, Launay D, Mouthon L, Jego P, Cabane J, de Groote P, Chabrol A, Lazareth I, Guillevin L, Clerson P, Humbert M; ItinérAIR-Sclérodermie Study Investigators. Hachulla E, et al. Rheumatology (Oxford). 2009 Mar;48(3):304-8. doi: 10.1093/rheumatology/ken488. Epub 2009 Jan 27. Rheumatology (Oxford). 2009. PMID: 19174571 Free PMC article.